Opinion|Videos|February 18, 2025
The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma
Panelists discuss the key toxicities influencing chimeric antigen receptor (CAR) T-cell therapy selection for early relapsed/refractory multiple myeloma (R/R MM), the transition to community care post treatment, strategies for managing toxicities, the future of CAR T in early R/R MM, and the impact of emerging data on treatment sequencing, along with insights from the DREAMM-7 and DREAMM-8 studies and improving the CAR T process in academic and community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your opinion, what does the future look like for CAR T in early R/R MM?
- How does emerging data impact your approach to treatment sequencing in early R/R MM?
- DREAMM-7, belantamab mafodotin plusVd in R/R MM after 1 prior LOT
- DREAMM- 8, Belantamab mafodotin plus Pd in R/R MM after 1 prior LOT
- What clinical pearls can you share on how the overall CAR T process can improve in both the academic and community setting?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
2
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
3
MYTHOS Misses Prespecified ORR End Point With T-DXd in HER2-Low Salivary Gland Carcinoma
4
Dr Ermann on Real-World Data for Zanubrutinib vs Acalabrutinib in Older CLL
5